{
  "id": 11241660,
  "title": "Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes",
  "url": "https://urgent.news/2026/10/01/efgartigimod-shows-sustained-efficacy-in-myasthenia-gravis-subtypes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T16:39:36.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/aanem/123224"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, data from the open-label...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}